NLRP3 and Alzheimer disease: Given the possible critical role of the NLRP3 inflammasome in the pathogenesis of AD, Wan et al. designed a dissolvable MN that could mediate transdermal delivery of CRISPR-Cas9-based genome-editing agents and dexamethasone for the effective treatment of AD 145.